MNTL Tema Neuroscience And Mental Health ETF
Quote as of Aug 06, 2025 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 23.74 | Day Range | 23.80 – 23.80 |
| 52-Week Range | 19.86 – 27.53 | Volume | 133 |
| Avg Volume | 83 | AUM | $10.3M (Oct 10, 2026) |
| Expense Ratio | 0.75% | Yield (TTM) | — |
| NAV | 23.37 | Premium/Discount | +1.86% indicative |
| Inception | Jan 22, 2024 | Holdings | 4 |
| Issuer | Tema | Exchange | NASDAQ |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 87975E875 | ISIN | — |
| Management | Actively managed (per issuer description) | ||
About this ETF
The actively managed Tema Neuroscience and Mental Health ETF seeks to provide long-term growth of capital by investing in companies tackling diseases of the central nervous system and mental health. The fund is designed to capitalize on innovation in treatments for CNS diseases.
Description from the fund data provider · profile as of Oct 10, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +2.01% | +10.03% | -5.63% | -2.70% | -9.13% | — | — | — | -4.36% |
| Total return | +2.01% | +10.03% | -5.63% | -2.70% | -8.21% | — | — | — | -4.35% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 08, 2025. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.75% | Annual cost of a $10,000 investment | $75.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 05, 2025 · portfolio reporting date from the data provider; holdings are not live positions. 42 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | VERTEX PHARMACEUTICALS, INC. | VRTX | 10.33% | 2.30K | $1.1M |
| 2 | REGENERON PHARMACEUTICALS, INC. | REGN | 8.09% | 1.49K | $831.6K |
| 3 | ALNYLAM PHARMACEUTICALS, INC. | ALNY | 7.74% | 1.98K | $796.4K |
| 4 | ARGENX SE | ARGX | 5.83% | 890 | $599.7K |
| 5 | NEUROCRINE BIOSCIENCES, INC. | NBIX | 4.89% | 3.90K | $503.3K |
| 6 | TEVA PHARMACEUTICAL INDUSTRIES LTD. | TEVA | 4.32% | 28.86K | $443.9K |
| 7 | ELI LILLY & CO. | LLY | 4.05% | 547 | $417.0K |
| 8 | CRINETICS PHARMACEUTICALS, INC. | CRNX | 3.54% | 13.07K | $363.8K |
| 9 | IONIS PHARMACEUTICALS, INC. | IONS | 3.48% | 8.32K | $357.9K |
| 10 | STRYKER CORP. | SYK | 3.22% | 877 | $331.3K |
| 11 | BIOGEN, INC. | BIIB | 3.21% | 2.50K | $330.0K |
| 12 | MEDTRONIC PLC | MDT | 2.59% | 2.98K | $265.9K |
| 13 | UCB SA | UCB.BR | 2.48% | 1.19K | $255.1K |
| 14 | ACADIA PHARMACEUTICALS, INC. | ACAD | 2.42% | 10.60K | $249.3K |
| 15 | CATALYST PHARMACEUTICALS, INC. | CPRX | 2.33% | 11.35K | $239.8K |
| 16 | AXSOME THERAPEUTICS, INC. | AXSM | 2.33% | 2.33K | $239.7K |
| 17 | CASH & CASH EQUIVALENTS | — | 2.08% | 0 | $213.8K |
| 18 | DENALI THERAPEUTICS, INC. | DNLI | 1.98% | 15.17K | $203.9K |
| 19 | AVIDITY BIOSCIENCES, INC. | RNA | 1.88% | 5.39K | $193.7K |
| 20 | JAZZ PHARMACEUTICALS PLC | JAZZ | 1.88% | 1.67K | $193.1K |
| 21 | XENON PHARMACEUTICALS, INC. | XENE | 1.81% | 6.11K | $186.4K |
| 22 | DEXCOM, INC. | DXCM | 1.72% | 2.23K | $176.9K |
| 23 | SCHOLAR ROCK HOLDING CORP. | SRRK | 1.71% | 4.84K | $175.8K |
| 24 | PTC THERAPEUTICS, INC. | PTCT | 1.58% | 3.12K | $162.9K |
| 25 | ALKERMES PLC | ALKS | 1.53% | 5.94K | $157.7K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | Irregular | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Dec 11, 2024 | Last payment | $0.2570 (Dec 12, 2024) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 11, 2024 | Dec 11, 2024 | Dec 12, 2024 | $0.2570 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | — / — | Sharpe 1Y / 3Y | — / — |
| Max drawdown 1Y / 3Y | — / — | Sortino 1Y | — |
| Beta vs S&P 500 (3Y) | 0.767 | Correlation vs S&P 500 (1Y) | — |
| Downside deviation 1Y | — | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 11, 2026. Formulas →
Liquidity
| Volume today | 133 | Average volume | 83 |
| AUM | $10.3M | Premium/Discount | +1.86% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for MNTL
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.